Clinical Trials Directory

Trials / Completed

CompletedNCT00232622

A Study Comparing a New Dosing Regimen of Clot-dissolving Drug for Mechanical Heart Valves Which Show Clots

A Prospective Randomized Trial of a Rapid Fibrinolytic Protocol for Left-sided Prosthetic Valve Thrombosis

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
120 (actual)
Sponsor
All India Institute of Medical Sciences · Academic / Other
Sex
All
Age
12 Years – 70 Years
Healthy volunteers
Not accepted

Summary

The optimal dosage and duration of administration of clot-dissolving medications for the treatment of patients with mechanical heart valves with clots is not known. We hypothesized that a large dose of the clot-dissolving medicine given initially (akin to the dose given in the treatment of heart attacks), might speed up the dissolution of the clot and rapidly restore the functioning of the mechanical heart valve.

Detailed description

The optimal fibrinolytic strategy for left sided prosthetic valve thrombosis (PVT) is not known. A large initial bolus dose of streptokinase (SK) might accelerate fibrinolysis and restore valve function more rapidly. This is a prospective, randomized trial comparing 2 fibrinolytic protocols in a first episode of PVT. In the rapid fibrinolytic protocol (RFP) 1.5 MU of SK is given over 1 hour, followed if required by a 0.1 MU/h infusion. In the standard protocol (SP) 0.25 MU is given over 30 minutes, followed by an infusion of 0.1 MU/h. Serial echocardiography and fluoroscopy will be done to monitor therapy. The primary end point is the occurrence of a complete clinical response (CCR, complete hemodynamic response without any major complication). 58 patients are required in each arm for detecting a 30% difference with 80% power at α=0.05.

Conditions

Interventions

TypeNameDescription
DRUGStreptokinaseAccelerated infusion of streptokinase
DRUGStreptokinaseStandard dose streptokinase

Timeline

Start date
2004-11-01
Primary completion
2007-03-01
Completion
2007-03-01
First posted
2005-10-05
Last updated
2013-10-24

Source: ClinicalTrials.gov record NCT00232622. Inclusion in this directory is not an endorsement.